 |
Find a Stock's Home Page |
|
| News |
SanDiego, CA Jul 09, 2009
The Small Cap Network (smallcapnetwork.com), a leading online investment community focused on small cap companies, has issued an analysis of Novogen Limited (NVGN) following Tuesday's announcement regarding phenoxodiol. The Malaghan Institute of Medical Research determined that abnormally proliferating human T-cells (rapidly dividing cancer cells) undergo a programmed death when briefly exposed briefly to Novogen's trial tumor drug phenoxodiol.
Investors and traders are invited to review more analytical coverage of Novogen Limited (NVGN) by subscribing to the free Small Cap Network Newsletter. The publication offers complete access to all commentary, market trend analysis, trading ideas and other useful market related insights by going to: access.smallcapnetwork.com/s/.
The results of this research suggest phenoxodiol is a candidate for the treatment of pathologically activated lymphocytes, or diseases driven by T-cell proliferation such as autoimmune diseases or graft-versus-host disease.
More about Novogen's investment opportunity can be reviewed at the Small Cap Network website.
About Novogen Limited
Novogen Limited (NVGN) is a pharmaceutical company involved in the discovery, development, manufacture and marketing of products based on the field of isoflavonoid technology. The Company's product development program embraces a range of pharmaceuticals based on a range of phenolic compounds and a range of consumer health care products based on plant compounds known as isoflavones. It directly markets consumer health care products in Australia, Canada and the United Kingdom. Novogen has entered into third party distribution arrangements in Singapore, South Africa, Austria, Ireland, Italy, Switzerland, Belgium and the Netherlands, and has licensed the United States rights to Promensil and Trinovin to Natrol, Inc. The Company's product range includes Phenoxodiol, Triphendiol, NV-128, NV-52, FAIMs, NV-27 and GLYC-101
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Small Cap Network is not a registered investment advisers or broker/dealer. Small Cap Network makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information: Small Cap Network 4653 Carmel Mtn. Rd Suite 308 #402 San Diego, CA 92130 Email: editor@smallcapnetwork.com
Source: Small Cap Network
http://community.smallcapnetwork.com/Small-Cap-Gains-in-a-Flat-Market-Drug-stocks-NVGN-and-TRGT-Post-Impressive-Gains/s/article/view/p/mid/1/id/133/: Small Cap Network e-mail: editor@smallcapnetwork.com
CONTACT
